Cidara Therapeutics IncNASDAQ:CDTX
- LAST PRICE20.2100
- TODAY'S CHANGE (%)0.0100 (0.0495%)
- Bid / Lots18.6000/ 15
- Ask / Lots20.8900/ 1
- Open / Previous Close20.2100 / 20.2000
- Day Range
- 52 Week Range
- Volume10,091
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CDTX |
|---|---|---|
| 09:32 ET | 275 | 20.21 |
| 09:33 ET | 173 | 19.7558 |
| 10:08 ET | 438 | 19.5926 |
| 10:36 ET | 200 | 20.19 |
| 10:42 ET | 241 | 20.29 |
| 10:56 ET | 195 | 20.312 |
| 11:07 ET | 100 | 20.45 |
| 11:09 ET | 349 | 20.5 |
| 11:14 ET | 230 | 19.9 |
| 11:25 ET | 691 | 20.5 |
| 11:34 ET | 152 | 20.22 |
| 11:36 ET | 1076 | 20.305 |
| 11:50 ET | 100 | 20.1101 |
| 12:03 ET | 492 | 20.2 |
| 12:32 ET | 500 | 20.1601 |
| 12:44 ET | 275 | 20.228 |
| 12:46 ET | 1000 | 20.322 |
| 12:57 ET | 100 | 20.5 |
| 01:00 ET | 455 | 20.21 |
Nov 21, 2024
DJ Cidara Therapeutics Shares Surge 26% on $105 Mln Private Placement, from 9:13AM ET on Thursday Nov 21, 2024 by Dow Jones
9:13AM ET on Thursday Nov 21, 2024 by Dow JonesCidara Therapeutics Announces $105 Million Private Placement, from 8:30AM ET on Thursday Nov 21, 2024 by Dow Jones
8:30AM ET on Thursday Nov 21, 2024 by Dow JonesPress Release: Cidara Therapeutics Announces $105 Million Private Placement, from 8:30AM ET on Thursday Nov 21, 2024 by Dow Jones
8:30AM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 19, 2024
Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference, from 8:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 11, 2024
DJ Cidara Therapeutics Price Target Maintained With a $24.00/Share by HC Wainwright & Co., from 7:56AM ET on Monday Nov 11, 2024 by Dow Jones
7:56AM ET on Monday Nov 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cidara Therapeutics Inc | 142.3M | -0.8x | --- |
Adaptimmune Therapeutics PLC | 174.0M | -3.4x | --- |
Innate Pharma SA | 123.0M | -3.5x | --- |
Enanta Pharmaceuticals Inc | 181.4M | -1.6x | --- |
MDxHealth SA | 97.0M | -1.3x | --- |
Repare Therapeutics Inc | 133.9M | -1.6x | --- |
Company Information
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.
Contact Information
- Headquarters
- 6310 Nancy Ridge Dr Ste 101SAN DIEGO, CA, United States 92121-3209
- Phone
- 858-752-6170
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Daniel Burgess
- President, Chief Executive Officer, Director
- Jeffrey Stein
- Chief Financial Officer
- Preetam Shah
- Chief Operating Officer, Company Secretary
- Shane Ward
- Chief Scientific Officer
- Leslie Tari
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $142.3M |
|---|---|
Revenue (TTM) | $18.9M |
Shares Outstanding | 7.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.13 |
EPS | $-26.06 |
Book Value | $-1.81 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 7.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -678.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
